Related references
Note: Only part of the references are listed.Anti-HK antibody reveals critical roles of a 20-residue HK region for A?-induced plasma contact system activation
Zu-Lin Chen et al.
BLOOD ADVANCES (2022)
Pharmacological reduction of coagulation factor XI reduces macrophage accumulation and accelerates deep vein thrombosis resolution in a mouse model of venous thrombosis
Kelley R. Jordan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)
Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice
Anh T. P. Ngo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Highly accurate protein structure prediction with AlphaFold
John Jumper et al.
NATURE (2021)
The evolution of factor XI and the kallikrein-kinin system
Michal B. Ponczek et al.
BLOOD ADVANCES (2020)
Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI
Chan Li et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Hydrogen-deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
Awital Bar Barroeta et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema
Daniel P. Teufel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
A. Banerji et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke
Fabricio Simao et al.
BLOOD (2017)
Site-specific O-Glycosylation Analysis of Human Blood Plasma Proteins
Marcus Hoffmann et al.
MOLECULAR & CELLULAR PROTEOMICS (2016)
Negatively charged silver nanoparticles cause retinal vascular permeability by activating plasma contact system and disrupting adherens junction
Yan-Min Long et al.
NANOTOXICOLOGY (2016)
A novel DFP tripeptide motif interacts with the coagulation factor XI apple 2 domain
Szu S. Wong et al.
BLOOD (2016)
Antithrombotic potential of the contact activation pathway
Alvin H. Schmaier
CURRENT OPINION IN HEMATOLOGY (2016)
The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities
A. H. Schmaier
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes
Ana Carolina B. Stefanini et al.
DISEASE MARKERS (2015)
The Phyre2 web portal for protein modeling, prediction and analysis
Lawrence A. Kelley et al.
NATURE PROTOCOLS (2015)
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
Jon A. Kenniston et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
The mechanism underlying activation of factor IX by factor XIa
David Gailani et al.
THROMBOSIS RESEARCH (2014)
Plasma kallikrein-kinin system and diabetic retinopathy
Jia Liu et al.
BIOLOGICAL CHEMISTRY (2013)
Analysis of the factorXI variant Arg184Gly suggests a structural basis for factorIX binding to factorXIa
Y. Geng et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Plasma kallikrein: the bradykinin-producing enzyme
Jenny Bjorkqvist et al.
THROMBOSIS AND HAEMOSTASIS (2013)
PAN-modular structure of microneme protein SML-2 from the parasite Sarcocystis muris at 1.95 Å resolution and its complex with 1-thio-β-D-galactose
Juergen J. Mueller et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Overview of the CCP4 suite and current developments
Martyn D. Winn et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
KNG1 Ile581Thr and susceptibility to venous thrombosis
Pierre-Emmanuel Morange et al.
BLOOD (2011)
LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery
Roman A. Laskowski et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
The Plasma Contact System 2.0
Coen Maas et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2011)
Common Variants of Large Effect in F12, KNG1, and HRG Are Associated with Activated Partial Thromboplastin Time
Lorna M. Houlihan et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2010)
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo
Qiufang Cheng et al.
BLOOD (2010)
Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor
Kusumam Joseph et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation
E. Hooley et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III
Sven Cichon et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Crystal structure of the factor XI zymogen reveals a pathway for transactivation
Evangelos Papagrigoriou et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
Identification of a binding site for glycoprotein Ibα in the Apple 3 domain of factor XI
FA Baglia et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2
T Renné et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2002)
Share Paper
